AC Immune (ACIU) Operating Expenses (2014 - 2026)

AC Immune (ACIU) has reported Operating Expenses for 12 consecutive years, with -$20.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 10.3% year-over-year to -$20.3 million; the TTM figure through Mar 2026 stood at -$85.1 million (up 5.58% YoY), while the FY2025 annual figure was -$87.9 million, up 3.35% from the prior year.
• Operating Expenses declined to -$20.3 million in Q1 2026 per ACIU's latest filing, from -$18.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at -$17.5 million in Q3 2023 and bottomed at -$25.0 million in Q2 2025.
• Historically, Operating Expenses has averaged -$20.8 million across 5 years, with a median of -$20.6 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses gained 21.46% — and 2024, when it slipped 26.27%.
• AC Immune's Operating Expenses stood at -$19.4 million in 2022, then dropped by 6.54% to -$20.7 million in 2023, then dropped by 9.06% to -$22.6 million in 2024, then increased by 18.26% to -$18.4 million in 2025, then declined by 10.21% to -$20.3 million in 2026.
• Business Quant data shows ACIU's Operating Expenses at -$20.3 million in Q1 2026, -$18.4 million in Q4 2025, and -$21.4 million in Q3 2025.